Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Thetis reports data supporting it IBD candidate

Thetis Pharmaceuticals reports preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD). TP-317 is a novel salt of Resolvin...

| By Kelley Gipson

Cybrexa data support its alphalex™ technology

Cybrexa Therapeutics reports preclinical data supporting the potential of its proprietary alphalex™ technology platform. Results from multiple preclinical studies demonstrate that alphalex™ successfully enables the combination...

| By Bill Kelly

BioCT welcomes new member Strategic Spaces

Strategic Spaces is a leader in prefabricated construction for interior spaces and commercial furniture solutions. With a trained team of interior designers and construction project...

| By Kelley Gipson

Gene therapy for liver disorder at UConn Health

The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction...

| By Bill Kelly

Gene therapy for liver disorder at UConn Health

The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction of...

| By Bill Kelly

BioCT Careers page matches employers and job seekers

Have you visited the BioCT Careers page recently? This enhanced, interactive site matches job seekers and employers in the bioscience industry throughout Connecticut. Job seekers...

| By Bill Kelly

Connecticut Innovations to invest in Invixium 

Connecticut Innovations reports that it has closed on the initial $665,000 tranche of a $1 million investment in Invixium Access, a manufacturer of modern biometric solutions. Invixium was a winner...

| By Kelley Gipson

SpringWorks announces Phase 3 trial re desmoid tumors

SpringWorks Therapeutics reports that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase...

| By Kelley Gipson

Azitra expands technical team in Farmington

Azitra has announced the appointment of two distinguished scientists to expand the technical team and lead the expansion of its development programs. Travis Whitfill, co-founder, will...